Public Employees Retirement Association of Colorado Sells 23,511 Shares of Moderna, Inc. (NASDAQ:MRNA)

Public Employees Retirement Association of Colorado lowered its holdings in Moderna, Inc. (NASDAQ:MRNAFree Report) by 32.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 48,967 shares of the company’s stock after selling 23,511 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Moderna were worth $4,870,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of MRNA. Quadrant Capital Group LLC lifted its holdings in Moderna by 7.5% during the fourth quarter. Quadrant Capital Group LLC now owns 2,672 shares of the company’s stock worth $266,000 after buying an additional 187 shares during the period. International Assets Investment Management LLC raised its holdings in Moderna by 6,528.9% in the fourth quarter. International Assets Investment Management LLC now owns 387,656 shares of the company’s stock worth $38,552,000 after purchasing an additional 381,808 shares in the last quarter. abrdn plc lifted its position in shares of Moderna by 477.5% during the fourth quarter. abrdn plc now owns 483,574 shares of the company’s stock valued at $48,091,000 after buying an additional 399,843 shares during the last quarter. Ontario Teachers Pension Plan Board bought a new stake in shares of Moderna in the 4th quarter valued at about $1,358,000. Finally, Van ECK Associates Corp grew its position in shares of Moderna by 19.2% in the 4th quarter. Van ECK Associates Corp now owns 270,774 shares of the company’s stock worth $26,929,000 after buying an additional 43,646 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $151.01 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91. The company’s fifty day moving average price is $124.66 and its 200 day moving average price is $105.79. Moderna, Inc. has a 1 year low of $62.55 and a 1 year high of $170.47.

Moderna (NASDAQ:MRNAGet Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, beating the consensus estimate of ($3.59) by $0.52. The firm had revenue of $167.00 million during the quarter, compared to analyst estimates of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. Moderna’s revenue for the quarter was down 91.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.19 EPS. Equities analysts forecast that Moderna, Inc. will post -7.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on MRNA. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Monday, June 3rd. UBS Group upped their target price on Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a research report on Tuesday, May 7th. Royal Bank of Canada boosted their price target on Moderna from $135.00 to $160.00 and gave the stock an “outperform” rating in a research note on Monday, June 3rd. William Blair reiterated a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Finally, Evercore ISI started coverage on shares of Moderna in a research note on Tuesday, May 14th. They set an “in-line” rating and a $120.00 price target on the stock. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Moderna currently has an average rating of “Hold” and a consensus target price of $128.02.

Read Our Latest Stock Analysis on Moderna

Insider Activity at Moderna

In other Moderna news, President Stephen Hoge sold 15,000 shares of the stock in a transaction on Monday, April 15th. The shares were sold at an average price of $105.02, for a total transaction of $1,575,300.00. Following the transaction, the president now directly owns 1,486,241 shares of the company’s stock, valued at $156,085,029.82. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Moderna news, Director Noubar Afeyan sold 20,000 shares of the company’s stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $145.08, for a total transaction of $2,901,600.00. Following the transaction, the director now directly owns 1,961,931 shares in the company, valued at $284,636,949.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $105.02, for a total value of $1,575,300.00. Following the transaction, the president now owns 1,486,241 shares of the company’s stock, valued at $156,085,029.82. The disclosure for this sale can be found here. In the last quarter, insiders have sold 218,245 shares of company stock valued at $26,083,172. 15.70% of the stock is owned by company insiders.

About Moderna

(Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Recommended Stories

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.